4//SEC Filing
Huh Yong-Jun 4
Accession 0001415889-24-019906
CIK 0001817241other
Filed
Jul 21, 8:00 PM ET
Accepted
Jul 22, 8:22 PM ET
Size
26.6 KB
Accession
0001415889-24-019906
Insider Transaction Report
Form 4
Huh Yong-Jun
Director
Transactions
- Conversion
Common Stock
2024-07-22+667,185→ 1,016,022 total(indirect: By GC Corp.) - Purchase
Common Stock
2024-07-22$12.00/sh+1,666,666$19,999,992→ 3,306,900 total(indirect: By GC Corp.) - Conversion
Series A Preferred Stock
2024-07-22−667,185→ 0 total(indirect: By GC Corp.)→ Common Stock (667,185 underlying) - Conversion
Common Stock
2024-07-22+330,095→ 1,346,117 total(indirect: By GC Corp.) - Conversion
Common Stock
2024-07-22+292,791→ 525,349 total(indirect: By GC Cell Corporation) - Conversion
Series B Preferred Stock
2024-07-22−330,095→ 0 total(indirect: By GC Corp.)→ Common Stock (330,095 underlying) - Conversion
Common Stock
2024-07-22+62,181→ 587,530 total(indirect: By GC Cell Corporation) - Other
Common Stock
2024-07-22$10.20/sh+294,117$2,999,993→ 1,640,234 total(indirect: By GC Corp.) - Purchase
Common Stock
2024-07-22$12.00/sh+416,666$4,999,992→ 1,260,512 total(indirect: By GC Cell Corporation) - Conversion
Series B Preferred Stock
2024-07-22−62,181→ 0 total(indirect: By GC Cell Corporation)→ Common Stock (62,181 underlying) - Conversion
Series A Preferred Stock
2024-07-22−292,791→ 0 total(indirect: By GC Cell Corporation)→ Common Stock (292,791 underlying) - Other
Common Stock
2024-07-22$10.20/sh+256,316$2,614,423→ 843,846 total(indirect: By GC Cell Corporation)
Footnotes (6)
- [F1]Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
- [F2]The shares are held directly by GC Corp. Mr. Yong-Jun Huh is Chief Executive Officer of GC Corp. GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by such entity, except to the extent of any pecuniary interest therein.
- [F3]Represents the conversion of outstanding simple agreement for future equity in the amount of $3,000,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.
- [F4]The shares were purchased in the Issuer's initial public offering.
- [F5]The shares are held directly by GC Cell Corporation. Mr. Yong-Jun Huh is Chief Executive Officer of GC Corp. GC Corp., a public Korean holdings company, which is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein.
- [F6]Represents the conversion of outstanding simple agreement for future equity in the amount of $2,614,424.28 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.
Documents
Issuer
Artiva Biotherapeutics, Inc.
CIK 0001817241
Entity typeother
Related Parties
1- filerCIK 0001931083
Filing Metadata
- Form type
- 4
- Filed
- Jul 21, 8:00 PM ET
- Accepted
- Jul 22, 8:22 PM ET
- Size
- 26.6 KB